Bleeding during anticoagulant and antiaggregation therapy as a cause of acute abdomen
Authors:
M. Hekerová
Authors‘ workplace:
Chirurgické oddělení, Nemocnice s poliklinikou Havířov, p. o.
primář: MUDr. B. Firla
Published in:
Rozhl. Chir., 2017, roč. 96, č. 10, s. 438-441.
Category:
Case Report
Overview
Pradaxa (dabigatrani etexilati mesilas) belongs to a new group of anticoagulants, its pharmacological properties enabling uniform dosage without a need for monitoring the anticoagulant effect. It is an oral direct thrombin inhibitor. Pradaxa is the first NOAC (new oral anticoagulant) with a specific reversal agent called Praxbind (idarucizumab).
Dabigatran is indicated for the prophylaxis of venous thromboembolism in elective hip or knee replacements, for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment of deep vein thrombosis and pulmonary embolism and also their recurrence in adult patients.
Key words:
dabigatrani etexilati − anticoagulant therapy – thromboembolism − idarucizumab
Sources
1. Janský P. Dabigatran etexilát – přelom v antitrombotické léčbě v kardiologii? Interv Akut Kardiol 2011;10:82−6.
2. Schulman S, Kearon C, Kakkar AK, et al. RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342–52.
3. Stangier J, Rathgen K, Stähle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64:292–303.
4. Reilly PA, Ivan Ryn J, Grottke O, et al. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects. Am J Med. 2016;129(11S):S64−72.
5. Rehman A, Awais M, Ul-Ain Baloch N. Idarucizumab: A novel antidote for reversal of dabigatran. Asian J Neurosurg 2016;11:66−7.
6. Pradaxa. Souhrn údajů o přípravku. www. sukl.cz.
7. Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015;373:511−20.
8. Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013;121:3554–62.
9. Praxbind. Souhrn údajů o přípravku. www. sukl.cz.
10. Krčová V, Hluší A, Palová M, et al. Nová antikoagulancia – možnosti monitorování antikoagulačního účinku (dabigatran). Interní Med 2012;14:318–21.
11. Jafri SM. Periprocedural thromboprophylaxis in patients receiving chronic anticoagulation therapy. American Heart Journal 2004;147:1–15.
Labels
Surgery Orthopaedics Trauma surgeryArticle was published in
Perspectives in Surgery
2017 Issue 10
Most read in this issue
- Complicated intraabdominal infections in surgical patients–empiric antimicrobial therapy management
- Clostridium difficile remains a medical challenge
- Bleeding during anticoagulant and antiaggregation therapy as a cause of acute abdomen
- Treatment of locally advanced rectal cancer – is it time for a change?